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Prediction of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease: An
Enhanced Model of BARD Score
Tae Hoon Lee*, Seung Hye Han†, Ju Dong Yang‡, Donghee Kim‡,§, and Monjur Ahmed∥
*Department of Internal Medicine, Marshall University School of Medicine, Huntington, WV, †Critical Care Medicine, National Institute of
Health, Bethesda, MD, ‡Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA, §Department of Internal Medicine,
Healthcare Research Institute, Seoul National University Hospital Healthcare System, Seoul, Korea, and ∥Division of Gastroenterology and
Hepatology, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA, USA

Background/Aims: The BARD score is a model to detect
advanced liver fibrosis in nonalcoholic fatty liver disease
(NAFLD) patients. The aims of this study were to identify additional factors and then to build an enhanced version of
the BARD score. Methods: One hundred seven patients with
biopsy-proven NAFLD were enrolled retrospectively. Logistic
regressions were performed to identify independent risk factors for advanced liver fibrosis (stage 3 or 4). An enhanced
model of the BARD score (BARDI score) was built and evaluated with a receiver operating characteristic (ROC) curve.
Results: In multivariate analysis, age (odds ratio [OR], 0.89;
p=0.04), aspartate aminotransferase/alanine aminotransferase ratio (OR, 1.73; p<0.01), and international normalized
ratio (INR) (OR, 8.85; p<0.01) were independently significant
factors. The BARDI score was created by adding the INR to
the BARD. The area under the ROC curve of the BARDI score
was significantly larger than that of the BARD score (0.881 vs
0.808, p<0.01). A BARDI score of 3 or more showed a positive predictive value (PPV) of 51.0% and a negative predictive
value (NPV) of 96.0%. Conclusions: The BARDI score had an
improved PPV over the BARD score and maintained an excellent NPV. Further study is warranted for its external validation
and comparison with other models. (Gut Liver 2013;7:323328)
Key Words: Non-alcoholic fatty liver disease; Liver cirrhosis;
International normalized ratio

INTRODUCTION
Nonalcoholic fatty liver disease (NAFLD) is the most common

type of liver disease in the developed countries. About 30% of
adults have this disease.1 The spectrum of NAFLD is diverse,
ranging from simple steatosis to nonalcoholic steatohepatitis
(NASH), which can lead to cirrhosis. The mainstream management strategy for NAFLD is regular follow-up with risk factor
modification and early detection of liver fibrosis.2 Therefore, the
early detection of liver fibrosis is very important.
The gold standard for detecting liver fibrosis is liver biopsy.
However this procedure is both risky and expensive, making it
difficult for patients to undergo repeated procedures.3,4 Further,
the NAFLD patients stay asymptomatic usually until its final
stages, making it difficult for the clinician to decide when to
recommend biopsy, which can result in delayed diagnosis and
management of liver cirrhosis. Several imaging methods which
use ultrasound, computed tomography or magnetic resonance
imaging (MRI) have been introduced to detect liver fibrosis early,5-10 but these methods are still expensive and available only
in limited places.
Several models using demographic and clinical variables
have been developed that can be used to predict liver fibrosis in
NAFLD patients. However, some of these were not made specifically for NAFLD patients,11-13 and some models require a liver
fibrosis panel which is not broadly used.12,14 The BARD score15
and the NAFLD fibrosis score16 are the models which were initially made specifically for NAFLD and do not require a special
test. The main strength of the BARD score over the NAFLD
fibrosis score is its simplicity. The components of the BARD
score: body mass index (BMI), aspartate aminotransferase (AST)/
alanine aminotransferase (ALT) ratio and diabetes, are all widely
available in clinical practices. The score can be added up simply,
without the use of a calculator. Considering the high prevalence
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of NAFLD, it is very important that general physicians have a
simple method to routinely screen patients for advanced liver
fibrosis. The limitation of the BARD score is its high false positivity. If a patient, for example, has diabetes and a BMI of 28
kg/m2 (BARD score, 2), this patient will be classified as having
a high risk of advanced liver fibrosis even though the patient
has an AST/ALT ratio of less than 0.8 and no liver fibrosis. The
positive predictive value (PPV) of a BARD score of 2 or more
was 43% for advanced liver fibrosis in its initial development.15
A prospective study has shown the PPV of a BARD score of
2 or more to be only 36.1% for advanced liver fibrosis, which
is lower than PPVs of other clinical models.5 This low PPV of
BARD score means that a significant number of patients will
have false positive results and may end up having unnecessary
imaging tests and risky liver biopsies.
In this study, we evaluated the performance of the BARD
score in our NAFLD patients and built an enhanced model of
the BARD score by finding additional variables in NAFLD patients.

MATERIALS AND METHODS
1. Data sources and elements
All patients with NASH, whose diagnoses were confirmed
by liver biopsy between 2002 and 2006 at Cabell Huntington
Hospital/Marshall University Medical Center, were enrolled retrospectively. The diagnostic criteria for NASH were used as described in literature previously.17 Any patients who had a history
of alcohol abuse in their medical records, serologic evidence of
hepatitis virus infection, or history of other liver disease, such as
hemochromatosis, alpha-1 antitrypsin deficiency, Wilsons’ disease, autoimmune hepatitis, primary biliary cirrhosis, or primary
sclerosing cholangitis, were excluded. Also the patients who
had an age of less than 18 years old at the time of biopsy were
excluded.
Demographics (age, sex, weight, and height), comorbidities
(hypertension, diabetes, and hyperlipidemia), and laboratory
information (liver profile, lipid profile, serum creatinine, and international normalized ratio [INR]) tested within a month before
the biopsy were obtained from the medical records. Hypertension, diabetes, and hyperlipidemia patients were defined as those
who were previously diagnosed with these diseases by physicians, or those who took antihypertensive medications, hypoglycemic agents/insulin, or lipid-lowering agents at the time of
biopsy. The liver profile, lipid profile and serum creatinine level
were measured using ADVIA® 1650 Chemistry System (Siemens
Healthcare Diagnostics, Deerfield, IL, USA). Protamine was measured using BCS® System (Siemens Healthcare Diagnostics). The
INR was calculated from the protamine level by SoftLab® (SCC
Soft Computer, Clearwater, FL, USA). Pathological reports made
by two pathologists for clinical purposes were used. The extent
of fibrosis was staged as follows: stage 0 was defined as no fi-

brosis. Enlarged fibrotic portal tracts were classified as stage 1.
Periportal or portal-portal septa but intact architecture was classified as stage 2. Fibrosis with architectural distortion without
cirrhosis as stage 3, and probable or definite cirrhosis as stage
4.17 We classified stages 3 and 4 fibrosis as advanced fibrosis
and stages 0, 1, and 2 as nonadvanced fibrosis. This study was
approved by Marshall University Institutional Review Board.
2. Statistical method
The chi-square test and Fisher’s exact test were used for the
categorical variables as appropriate, and a Wilcoxon rank sum
test was used for the continuous variables to compare between
advanced and nonadvanced fibrosis groups. A box plot was created to show the relationship between variables and the severity
of fibrosis. The variables which were significantly associated
with the severity of fibrosis in univariate analyses were selected
for the multivariate logistic regression. A Wald chi-square test
was used for the statistical significance testing in the logistic
regression.
The independent predictors in our multivariate model were
incorporated into the BARD score model to make an enhanced
model. A receiver operating characteristics (ROC) curve was
plotted for both the BARD score model and our enhanced model
to evaluate their abilities to identify advanced fibrosis in NAFLD
patients. The area under the ROC curve (AUROC) was calculated
and a likelihood ratio test was performed to compare the models. As an independent validation data set was not available, a
20-fold cross validation was performed as internal validation.18
A p-value of 0.05 was used as the cutoff of statistical significance. Statistical analyses were conducted using the SAS
9.1 statistical software package (SAS Institute, Cary, NC, USA).
SPSS version 13.0 (SPSS Inc., Chicago, IL, USA) was used to
create the box plot and ROC curve.

RESULTS
Of the 135 patients who were identified initially, 28 of patients were excluded because of our exclusion criteria: 10 alcoholic hepatitis, nine viral hepatitis, six pediatric patients, two
hemochromatosis, and one patient with lack of data. Finally,
107 patients were included in this study. Twenty-two patients
had stage 0 fibrosis, 20 patients had stage 1, 31 patients had
stage 2, 18 patients had stage 3, and 16 patients had stage 4 fibrosis. As shown in Table 1, the median age was 48.9. Most (79%)
of the patients had a BMI of more than 28 kg/m2 and there were
more females than males in both of nonadvanced and advanced
fibrosis groups. Age, BMI, and sex did not show any significant
difference between the two groups. Of the laboratory test results, ALT, AST/ALT ratio, bilirubin, INR, cholesterol, and high
density lipoprotein levels were significantly different between
the advanced and nonadvanced liver fibrosis groups.
Of the comorbidities, only hypertension was significantly
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Table 1. Demographic and Clinical Characteristics of Patients
Characteristic

Total

Nonadvanced (n=73)

Advanced (n=34)

p-value*

Age, yr

48.9 (40.9–50.0)

48.2 (39.7–54.5)
n=73

50.5 (42.3–58.2)
n=34

0.14

BMI, kg/m2

35.9 (29.6–44.7)

35.08 (28.82–43.82)
n=63

40.97 (31.35–52.78)
n=31

0.08

Male sex

41 (38.3)

27 (37)
n=73

14 (41)
n=34

0.68

AST, U/L

55.0 (36.0–81.0)

55.0 (39.0–81.0)
n=65

54.5 (30.0–80.0)
n=34

0.48

ALT, U/L

63.0 (29.0–105.0)

75.0 (42.0–122.0)
n=65

33.5 (26.0–69.0)
n=34

<0.01

AST/ALT ratio

0.90 (0.68–1.31)

0.74 (0.62–1.08)
n=65

1.25 (0.99–1.56)
n=34

<0.01

Bilirubin, mg/dL

0.50 (0.40–0.80)

0.40 (0.30–0.60)
n=64

0.60 (0.40–1.00)
n=34

0.01

INR

1.02 (0.95–1.14)

0.97 (0.94–1.05)
n=64

1.14 (1.05–1.46)
n=31

<0.01

Creatinine, mg/dL

1.00 (0.90–1.10)

1.00 (0.90–1.10)
n=62

1.00 (0.90–1.10)
n=33

0.44

183.5 (162.0–219.0)

202.0 (168.0–222.0)
n=35

172.0 (151.0–199.0)
n=21

0.05

LDL, mg/dL

106 (85.5–133.0)

116.0 (87.0–145.0)
n=35

101.0 (82.0–117.0)
n=21

0.10

HDL, mg/dL

42.5 (35.0–50.5)

47.0 (35.0–57.0)
n=35

38.0 (35.0–43.0)
n=21

0.03

157.0 (115.0–255.0)

159.0 (128.5–278.5)
n=36

140.0 (98.0–207.0)
n=21

0.15

Total cholesterol, mg/dL

Triglyceride, mg/dL
Diabetes

34 (32.7)

21 (29.2)

13 (40.6)

0.25

Hypertension

51 (49.0)

30 (41.7)

21 (65.6)

0.02

Hyperlipidemia

30 (28.9)

17 (23.6)

13 (41.6)

0.08

Data are presented as medians (interquartile ranges) or number (%).
BMI, body mass index; AST, aspartate aminotransferase; ALT, alanine aminotransferase; INR, international normalized ratio; LDL, low density
lipoprotein; HDL, high density lipoprotein.
*Comparison between nonadvanced vs advanced disease. Chi-square tests for sex, diabetes, hypertension, and hyperlipidemia. Wilcoxon RankSum tests for other variables.

different between the two fibrosis groups. About 33% of the
patients had diabetes. The difference in frequencies of diabetes
and hyperlipidemia between the two fibrosis groups didn’t reach
a level of statistical significance (Table 1).
Age, BMI, AST/ALT ratio, INR, bilirubin, cholesterol, diabetes,
and hypertension were included initially in multivariate logistic
regression. Age, BMI, and diabetes were included because these
had been the important variables in the previous studies. After
stepwise selection, age, AST/ALT ratio, and INR were the independently significant factors for advanced fibrosis. Bilirubin,
diabetes, and hypertension were not independently significant,
even though these variables remained in the final model (Table
2).
The BARD score was calculated and its ROC curve was created using our study sample. An enhanced model of BARD
score, BARDI score, was generated by adding the INR to the

components of the BARD score model. To keep the character
of the BARD score, the same criteria (BMI ≥28 kg/m2 and AST/
ALT ratio ≥0.8) were used in the BARDI score. For the INR, the
ROC curve was generated and the maximum point of sensitivity plus specificity was chosen as a cutoff (INR, 1.07). Forced
entry multivariate logistic regression was performed again using BMI, AST/ALT ratio, diabetes and INR. The coefficients (β)
of variables in this multivariate logistic regression were used
for the BARDI scoring system. AST/ALT ≥0.8 (β=3.21) received
three credits, diabetes (β=1.22) received one credit, and an INR
2
≥1.07 (β=2.01) received two credits. A BMI ≥28 kg/m (β=0.12)
received one credit even with a low β in order to keep the character of the BARD score in the BARDI score. The ROC curve of
this BARDI model showed better performance than the BARD
model (Fig. 1). The AUROC of the BARDI model was significantly better than the AUROC of the BARD model (0.881 vs
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Table 2. Multivariate Logistic Regression Analysis for the Prediction
of Advanced Liver Fibrosis

Table 3. Comparison between BARD and BARDI Scores Using Our
Study Sample

Multivariate
OR (95% CI)
Age

p-value*

0.89 (0.79–1.00)
†

AST/ALT ratio

1.73 (1.17–2.56)

Bilirubin

0.09 (0.01–1.04)
‡

PPV

NPV

BARD
≥0

1.000

0.000

0.355

1.000

<0.01

≥1

1.000

0.082

0.375

1.000

0.05

≥2

1.000

0.347

0.458

1.000

≥3

0.852

0.673

0.590

0.892

≥4

0.333

0.918

0.692

0.714

≥0

1.000

0.000

0.355

1.000

≥1

1.000

0.082

0.375

1.000

≥2

1.000

0.327

0.450

1.000

≥3

0.963

0.490

0.510

0.960

≥4

0.926

0.612

0.568

0.938

≥5

0.852

0.796

0.697

0.907

≥6

0.704

0.878

0.760

0.843

≥7

0.259

0.980

0.875

0.706

8.85 (1.77–44.11)

<0.01

Diabetes

9.08 (0.62–131.93)

0.11

13.80 (0.82–233.29)

Specificity

0.04

INR
Hypertension

Sensitivity

0.07

Stepwise selection after including age, body mass index, AST/ALT
ratio, INR, bilirubin, cholesterol, diabetes, and hypertension. The AST/
ALT ratio and INR were multiplied by 10 to match the interval scale
with other variables.
OR, odds ratio; CI, confidence interval; AST, aspartate aminotransferase; ALT, alanine aminotransferase; INR, international normalized
ratio.
*Wald chi-square test; †OR for the 0.1 change of AST/ALT ratio; ‡OR
for the 0.1 change of INR.

BARDI

BARD area under receiver operating characteristic curve 0.808. BARDI area under receiver operating characteristic curve 0.881. BARDI
score is the sum of the points below.
If body mass index ≥28 kg/m2, then 1 point. If aspartate aminotransferase/alanine aminotransferase ratio ≥0.8, then 3 points. If diabetes
present, then 1 point. If international normalized ratio ≥1.07, then 2
points.
PPV, positive predictive value; NPV, negative predictive value.

Fig. 1. Receiver operating characteristic (ROC) curve of BARD and
BARDI score for advanced liver fibrosis. Area under ROC curve for
BARDI model, 0.881 (95% confidence interval [CI], 0.804 to 0.958).
Area under ROC curve for BARD model, 0.808 (95% CI, 0.712 to 0.904).
Seventy-six patients were used for this ROC curve after the exclusion
of patients with missing values.
*Likelihood ratio test.

0.808, p<0.01). Comparing a BARD score of 2 or more with a
BARDI score of 2 or more, the PPV was 45.8% for the BARD
and 45.0% for the BARDI, which were not much different in
our subjects. The negative predictive values (NPV) were 100%
in both the BARD and BARDI scores. When comparing a BARDI
score of 3 or more with a BARD of score 2 or more, the BARDI
score showed higher specificity (49.0% vs 34.7%) without losing
much sensitivity (96.3% vs 100%). The PPV for a BARDI score
of 3 or more was 51.0%, while the PPV for a BARD score of 2
or more was 45.8%. The NPV for a BARDI score of 3 or more
was 96.0% and NPV for a BARD score of 2 or more was 100%

(Table 3). Twenty fold cross validation of the BARDI model
showed 80.39% accuracy with a standard error of 0.75%. We
tried to incorporate age, bilirubin, and hypertension respectively
into the BARDI model. However, these variables did not increase
the AUROC significantly and were not included in the final
model (data not shown).

DISCUSSION
We developed an enhanced model (BARDI score), by adding
the INR, which was known to have correlation with liver fibrosis.13,16 As shown in Table 3, the BARDI score kept the simplicity
and strength of the BARD score. All patients with a BARD score
of 2 or more should have a BARDI score of 2 or more. A BARDI
score of 2 or more performed similarly to a BARD score of 2 or
more. When a BARDI score of 3 or more was compared with a
BARD score of 2 or more, the BARDI score showed an improved
PPV and kept an excellent NPV for detecting advanced liver
fibrosis.
Using 2 or more of the BARD score is just the same as having
one of either two risk factors (obesity and diabetes) or an AST/
ALT ratio ≥0.8 as criteria for advanced fibrosis. If the patient has
two risk factors with an AST/ALT ratio less than 0.8, the patient
will be classified as high risk for advanced fibrosis. Usually,
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Table 4. Previously Reported Models for Advanced Liver Fibrosis in NAFLD
Model

Variable

11,

Cut-off AUROC Sensitivity, % Specificity, % PPV, % NPV, %

BAAT *

BMI, age, ALT, triglycerides

1

0.84

47

45

FIB-45,†

Age, AST, ALT, platelet

1.30

0.80

65.1

80.2

50.6

88.0

OELF

Age, P3NP, TIMP-1, HA

0.375

0.87

89

96

80

98

ELF14

P3NP, TIMP-1, HA

0.3576

0.90

80

90

71

94

14

16

100

100

NAFLD fibrosis score

Age, BMI, IFG or DM, AST/ALT, platelet, albumin

-1.455

0.88

82

77

56

93

ELF+NAFLD fibrosis
score14

P3NP, TIMP-1, HA, BMI, IFG or DM, AST/ALT,
platelet, albumin

-0.2826

0.98

91

96

77

99

BARD score15

BMI, AST/ALT, DM

≥2

0.81

NA

NA

43

96

NAFLD, nonalcoholic fatty liver disease; AUROC, area under receiver operating characteristic curve; PPV, positive predictive value; NPV, negative
predictive value; BMI, body mass index; ALT, alanine aminotransferase; AST, aspartate aminotransferase; P3NP, amino-terminal propeptide of
type III collagen; TIMP-1, tissue inhibitor of matrix metalloproteinase 1; HA, hyaluronic acid; IFG, impaired fasting glucose; DM, diabetes mellitus; NA, not available.
*AUROC, PPV, NPV were calculated to detect stage 2 or higher; †AUROC, PPV, NPV data were from the study.

diabetic patients have a high prevalence of obesity.19 All these
obese diabetic patients will be classified into the high risk group
for advanced fibrosis, which will result in a lot of false positivity. In our study, we had a skewed population in terms of BMI
and most patients received a credit due to obesity (BMI ≥28).
Among the patients with both diabetes and obesity in our study
(n=27), many patients (n=11, 40.7%) would have a BARD score
of 2, even though they did not have advanced liver fibrosis.
In contrast, a BARDI score of 3 or more cannot be made from
the risk factors alone. Risk factors need to be combined with
an INR ≥1.07 to reach a score of 3 or more. This combination
is the main reason why the BARDI score can decrease the false
positivity (increase PPV) of the BARD score. The role of AST/
ALT ratio was kept the same in the BARDI score as in the BARD
score. Any patient with an AST/ALT ratio of 0.8 or more should
be classified into the possible advanced liver fibrosis group in
either scoring system.
Age,11-13,16 platelet count,13 albumin,16 bilirubin,13,16 triglyceride,11 impaired fasting glucose level,16 and hypertension15,16 are
known to be associated with advanced liver fibrosis and some
of them have been used in other models, as shown in Table 4.
In our study, we didn’t have enough data for platelet, albumin
and were not able to compare BARDI score directly with other
models including NAFLD fibrosis score16 or FIB-4 score.13 As our
patients did not have liver fibrosis panel, it was also not possible
to compare the BARDI score with any models (OELF,12,14 ELF14
models) that used the liver fibrosis panel. Indirect comparison of
PPV and NPV was also not possible because the PPV and NPV
would be affected by the prevalence of advanced liver fibrosis
in each study. However, the indirect comparison of sensitivity and specificity between models showed promising results.
For example, an NAFLD fibrosis score showed 82% sensitivity
and 77% specificity. A BARDI score of 3 or more showed 96%
sensitivity and 49% specificity. When it comes with the BARDI
score of 5 or more, the BARDI showed 85% sensitivity and
79.6% specificity. When the AUROC was compared using the

previously reported AUROCs of other models, the AUROC 0.881
of the BARDI score was at least comparable with other models
(Table 4).
Other imaging studies including ultrasound based transient
elastography (FibroScan), MR spectroscopy, diffusion weighted
MRI, and MR elastography have been developed.9 It has been
shown that these imaging methods have slightly better or
comparable results to clinical models. In the case of transient
elastography, the AUROC was reported to be 0.9047 and 0.94.5
In particular, Wong et al. 5 showed the superiority of transient
elastography to other previous clinical models for the diagnosis
of advanced liver fibrosis. However, these imaging techniques
cost more expenses and limited to only a small number of centers. Considering that NAFLD is a very common disease with
a prevalence of about 30%,1 there should be a way that clinicians can evaluate a patient’s risk of liver fibrosis in their offices
before they refer them to specialized centers. If the assessment
can be done using simple usual lab tests, many at risk patients
can be detected or excluded before they go for an imaging test.
After first screening with a clinical model, a physician still can
perform imaging tests, which can give some information before
the liver biopsy. An imaging test can differentiate a diffuse lesion from a local lesion and can also provide information about
the character of a localized lesion, including possible mass like
lesion, infection and so on. Then patient can opt for biopsy if it
is indicated through the clinical model and imaging test.
Our study had several limitations. We had only 107 patients
to analyze, which made it hard to split our subjects for external validation. Instead, we performed 20-fold cross validation,
which showed a good performance of the BARDI score. Another
limitation was derived from the restrictions of retrospective
study. All information was gathered using the medical records
which had been produced for clinical purposes only. The information was not complete enough to compare several previous
models using our study subjects. We were able to calculate only
the BARD score for our subjects. Also some medical records
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were not detailed regarding alcohol consumption. We had to
exclude any patients who drank unspecified amounts of alcohol
from our study. Also, our study was based on patients who had
already had liver biopsies, indicating that the studies subjects
may be sicker than the general population. Actually, all previous clinical models were made using the patient population who
had received or had decided to have liver biopsy as well. The
performance of these models should be evaluated prospectively
in general population.
In conclusion, the INR was an independently significant factor for advanced liver fibrosis. We developed the BARDI score
by adding the INR to the BARD score, resulting in an enhanced
model that was still easy to calculate and had better performance than the BARD in predicting advanced liver fibrosis.
Using the BARDI score would decrease false positivity with an
excellent NPV, and eventually prevent unnecessary imaging
tests or risky liver biopsies. Further external validation study
and prospective study are needed to confirm this finding.
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